Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
One-size-fits-all cancer care doesn't work everywhere. At the 2026 World Cancer Congress in Hong Kong, the NCCN presented research showing that National Cancer Control Plans need regionally adapted guidelines — and demonstrated how it worked with Chinese experts to tailor head and neck cancer recommendations for China's unique clinical landscape.
At the 2026 World Cancer Congress in Hong Kong, the National Comprehensive Cancer Network (NCCN) presented two research abstracts making the case that effective cancer care requires more than universal guidelines — it requires regional adaptation. The first study found that while 61% of active National Cancer Control Plans (NCCPs) reference existing cancer treatment guidelines, most lack systems to measure implementation, and few adequately address disease staging — a critical gap for tracking trends and designing interventions.
The second abstract showcased a real-world example: NCCN partnered with oncologists at Sun Yat-sen University Cancer Center in China to adapt its Head and Neck Cancer guidelines specifically for nasopharyngeal carcinoma — a cancer far more prevalent in China than the U.S. due to EBV-related, genetic, and environmental factors. The adapted guidelines incorporate China-specific medications and expanded systemic and radiation therapy recommendations.
By the Numbers:
Why it matters: Tailoring evidence-based cancer guidelines to regional realities — accounting for local disease burden, available treatments, and clinical experience — can meaningfully improve cancer outcomes for patients worldwide, particularly in high-burden regions like China.
